Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jul 24, 2021 5:31pm
609 Views
Post# 33601298

Additional thoughts on the ATM

Additional thoughts on the ATMIf the meetings with US institutions went verry well last week (and I could see how that might be the case) those institutions might be pressing THTX to sell them shares. But if THTX was going to do that, why would they set up an ATM? Why not just do a regular offering under the current $150 million shelf offering that I am pretty sure is still in place? Since this is apparently not the case, it seems to me they intend to sit on this ATM option until a more optimal time to sell shares, just like they have sat on the shelf offering for nearly two years. 

In the last conference call, the words "shareholder value" made an appearance. Those words have not been uttered a lot by THTX management over the years and I was heartened to see them make an appearance. Hopefully, we will see them back up those words with action and continue to process of rebuilding their credibility with investors. Everything will be easier for Paul and the board in the years to come if they are able to rebuild that credibility and everything will be harder if they blow it up once more. 

There is a classic proverb in the Bible; "As a dog returns to its vomit, so a fool returns to its folly". Let's hope THTX management and board do not return to their previous folly. 

I have asked Leah Gibson to priovide any context she can regarding the deal and will pass along anything she might offer in that regard.
<< Previous
Bullboard Posts
Next >>